Deal net: 13 – 17 February 2017
Posted on 17 February, 2017 by Thierry Heles, editor
The Global Government Venturing deal net rounds up all the latest smaller deals and tracks emerging companies accessing government funds.
Demooz, a France-based platform that enables users to test a product ahead of a purchase, has raised €800,000 ($850,000) from investors including Bpifrance, the public investment bank of France, Maddyness has reported. ZTP and Side Capital also participated in the round, which follows a €210,000 injection in 2015 from Bpifrance and Réseau Entreprendre Aquitaine, owned by the Aquitaine regional government. Demooz connects potential customers to other users nearby who already own a product, so they can try it out. The money will help the startup accelerate its growth in France and internationally.
Desentum, a Finland-based biopharmaceutical company spun out of public research institute VTT Technical Research Centre of Finland, has closed a €2m series A round that included government agency VTT Ventures, Cascara Ventures, Acme Investments and Sto-Rahoitus, as well as the founding shareholders. Desentum is working on immunotherapies to treat patients suffering from allergies.
Cebiotex, a Spain-based post-surgery cancer treatment developer spun out of Hospital Sant Joan de Déu and Universitat Politècnica de Catalunya, has raised €1.8m in funding to finance the regulatory pre-clinical phase of its lead candidate. The money was provided by the Neotec Center Industrial Technological Development program and Enisa, under the Ministry of Economy, Industry and Competitiveness and the European Commission’s Horizon 2020 program. Fundació Ship2B, Inveready, family offices and two parallel campaigns of equity crowdfunding with Capital Cell also supplied cash.
University College Dublin spinout OncoMark, the developer of a panels of cancer biomarkets to enable more personalised treatment decisions, has received €2.1m in funding from Kernel Capital, through the Bank of Ireland Kernel Capital Venture Funds, Irrus Investments, Galway HBAN MedTech, private investors and Enterprise Ireland, the state-owned export credit agency. The funding will support the commercialisation of the spinout’s lead product, OncoMasTR, slated for release in 2018, that offers a prognostic test for early-stage breast cancer. OncoMark is based on research conducted by William Gallagher and Steve Penney at the School of Biomolecular and Biomedical Science.
Copyright Mawsonia Limited 2010. Please don't cut articles from www.globalgovernmentventuring.com or the PDF and redistribute by email or post to the web without written permission.
Latest magazinePast Issues
Get full online access, the monthly magazine, weekly news alerts, special reports and more.See all subscription options
February 06, 2017
January 24, 2017
January 25, 2017
January 30, 2017
January 26, 2017